Cancer vaccines in hematologic malignancies: advances, challenges and therapeutic potential

References

• Boeck S, Hamann M, Pihusch V et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood75(3), 555–562 (1990).
   Google Scholar
• Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med.300(19), 1068–1073 (1979).
   PubMed Web of Science ®Google Scholar
• Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol.15(2), 433–444 (1997).
   PubMed Web of Science ®Google Scholar
• Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood87(3), 1196–1198 (1996).
   PubMed Web of Science ®Google Scholar
• Speiser DE, Miranda R, Zakarian A et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med.186(5), 645–653 (1997).
   PubMed Web of Science ®Google Scholar
• Avigan D. Vaccine therapy and adoptive immunotherapy in hematologic malignancies. Best Pract. Res. Clin. Haematol.21(3), 373–374 (2008).
   Google Scholar
• Brossart P, Schneider A, Dill P et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res.61(18), 6846–6850 (2001).
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Arfsten J, Cao Y et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood109(3), 1103–1112 (2007).
   PubMed Web of Science ®Google Scholar
• Batchu RB, Moreno AM, Szmania SM et al. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Res.65(21), 10041–10049 (2005).
   PubMed Web of Science ®Google Scholar
• Barrett AA, Rezvani K. Translational mini-review series on vaccines: peptide vaccines for myeloid leukaemias. Clin. Exp. Immunol.148(2), 189–198 (2007).
   PubMed Web of Science ®Google Scholar
• Baskar S, Kwong KY, Hofer T et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin. Cancer Res.14(2), 396–404 (2008).
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Li L, Bojarska-Junak A, Rolinski J et al. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. Int. J. Oncol.29(1), 95–103 (2006).
   PubMed Web of Science ®Google Scholar
• Schmidt SM, Schag K, Müller MR et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood102(2), 571–576 (2003).
   PubMed Web of Science ®Google Scholar
• Inoue K, Sugiyama H, Ogawa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood84(9), 3071–3079 (1994).
   PubMed Web of Science ®Google Scholar
• Sturrock AB, Franklin KF, Rao G et al. Structure, chromosomal assignment, and expression of the gene for proteinase-3. The Wegener’s granulomatosis autoantigen. J. Biol. Chem.267(29), 21193–21199 (1992).
   Google Scholar
• Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol. Rev.157, 125–140 (1997).
   PubMed Web of Science ®Google Scholar
• Qazilbash MH, Wieder E, Rios Ret al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia [abstract]. Blood. ASH Ann. Meeting Abstracts104, 259 (2004).
   Google Scholar
• Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA101(38), 13885–13890 (2004).
   PubMed Web of Science ®Google Scholar
• Morita S, Oka Y, Tsuboi A et al. A Phase I/II trial of a WT1 (Wilms’ tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the Phase I data. Jpn J. Clin. Oncol.36(4), 231–236 (2006).
   PubMed Web of Science ®Google Scholar
• Palena C, Foon KA, Panicali D et al. Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. Blood106(10), 3515–3523 (2005).
   PubMed Web of Science ®Google Scholar
• Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J. Clin. Invest.101(5), 1133–1141 (1998).
   PubMed Web of Science ®Google Scholar
• Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood96(9), 2917–2924 (2000).
   PubMed Web of Science ®Google Scholar
• Ho VT, Vanneman M, Kim H et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc. Natl Acad. Sci. USA106(37), 15825–15830 (2009).
   PubMed Web of Science ®Google Scholar
• Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev.13(1), 51–64 (1999).
   PubMed Web of Science ®Google Scholar
• Lonial S, Torre C, David E, Harris W, Arellano M, Waller EK. Regulation of alloimmune responses by dendritic cell subsets. Exp. Hematol.36(10), 1309–1317 (2008).
   PubMed Web of Science ®Google Scholar
• Jarnjak-Jankovic S, Pettersen RD, Saebøe-Larssen S, Wesenberg F, Gaudernack G. Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemia. BMC Cancer5, 20 (2005).
   PubMedGoogle Scholar
• Albert MM, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature392(6671), 86–89 (1998).
   PubMed Web of Science ®Google Scholar
• Lee JJ, Choi BH, Kang HK et al. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leuk. Lymphoma48(10), 2022–2031 (2007).
   PubMed Web of Science ®Google Scholar
• Dabadghao S, Bergenbrant S, Anton D, He W, Holm G, Yi Q. Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br. J. Haematol.100(4), 647–654 (1998).
   PubMed Web of Science ®Google Scholar
• Vasir B, Borges V, Wu Z et al. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br. J. Haematol.129(5), 687–700 (2005).
   PubMed Web of Science ®Google Scholar
• Gong J, Koido S, Chen D et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood99(7), 2512–2517 (2002).
   PubMed Web of Science ®Google Scholar
• Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med.3(5), 558–561 (1997).
   PubMed Web of Science ®Google Scholar
• Avigan D. Phase I study of vaccination with dendritic cell myeloma fusions. Blood. ASH Ann. Meeting Abstracts110, 284 (2007).
   Google Scholar
• Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell101(5), 455–458 (2000).
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Giese T et al.In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood107(10), 3940–3949 (2006).
   PubMed Web of Science ®Google Scholar
• Vasir B, Wu Z, Crawford K, Rosenblatt J et al. Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells. J. Immunol.181(1), 808–821 (2008).
   PubMed Web of Science ®Google Scholar
• Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor a) monoclonal antibody. Cancer Res.59(13), 3128–3133 (1999).
   PubMed Web of Science ®Google Scholar
• Rezvani K, Mielke S, Ahmadzadeh M et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood108(4), 1291–1297 (2006).
   PubMed Web of Science ®Google Scholar
• Mielke S, Rezvani K, Savani BN et al. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood110(5), 1689–1697 (2007).
   PubMed Web of Science ®Google Scholar
• Cozzo C, Larkin J 3rd, Caton AJ. Cutting edge: self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J. Immunol.171(11), 5678–5682 (2003).
   PubMed Web of Science ®Google Scholar
• Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood110(9), 3192–3201 (2007).
   PubMed Web of Science ®Google Scholar
• Mahnke K, Schönfeld K, Fondel S et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer120(12), 2723–2733 (2007).
   PubMed Web of Science ®Google Scholar
• Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest.115(12), 3623–3633 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Avivi I, Vasir B et al. Dendritic cell tumor fusion vaccination in conjunction with autologous transplantation for multiple myeloma. Blood. ASH Ann. Meeting Abstracts114, 783 (2009).
   Google Scholar
• Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol.8(3), 239–245 (2007).
   PubMed Web of Science ®Google Scholar
• Shin EE, Rehermann B. Taking the brake off T cells in chronic viral infection. Nat. Med.12(3), 276–277 (2006).
   Google Scholar
• Ribas A, Comin-Anduix B, Chmielowski B et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin. Cancer Res.15(19), 6267–6276 (2009).
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol.19, 683–765 (2001).
   PubMed Web of Science ®Google Scholar
• Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-β regulation of immune responses. Annu. Rev. Immunol.24, 99–146 (2006).
   PubMed Web of Science ®Google Scholar
• Terabe M, Matsui S, Noben-Trauth N, Chen H. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway. Nat. Immunol.1(6), 515–520 (2000).
   PubMed Web of Science ®Google Scholar
• Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol.4(12), 941–952 (2004).
   PubMed Web of Science ®Google Scholar
• Zheng R, Cohen PA, Paustian CA et al. Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res.68(11), 4045–4049 (2008).
   PubMedGoogle Scholar
• Li Y, Zhi W, Wareski P, Weng NP. IL-15 activates telomerase and minimizes telomere loss and may preserve the replicative life span of memory CD8+ T cells in vitro. J. Immunol.174(7), 4019–4024 (2005).
   Google Scholar
• Anichini A, Scarito A, Molla A, Parmiani G, Mortarini R. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common γ-chain cytokines. J. Immunol.171(4), 2134–2141 (2003).
   Google Scholar